Status: Recruiting
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Participants needed: 160
Trial details
Phase: Phase 1Age: 60-85Biological sex: AllType: InterventionalSponsor: Clover Biopharmaceuticals USA, LLCUpdated: May 14, 2025Locations: 5
Eligibility criteria
Male and female participants 60-85 years of age at the screening visit and who r... [+3]
Acute disease or fever (≥38°C) at time of vaccination. Participants with a minor... [+4]